Axsome Therapeutics Inc (NASDAQ: AXSM) has experienced a decline in its stock price by -5.72 compared to its previous closing price of 69.71. However, the company has seen a fall of -8.38% in its stock price over the last five trading days. Zacks Investment Research reported 2024-04-02 that Axsome’s (AXSM) phase III ENGAGE study is set to evaluate the efficacy and safety of solriamfetol for the treatment of binge eating disorder in adults.
Is It Worth Investing in Axsome Therapeutics Inc (NASDAQ: AXSM) Right Now?
The 36-month beta value for AXSM is at 1.14. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for AXSM is 38.78M, and currently, shorts hold a 19.73% of that float. The average trading volume for AXSM on April 19, 2024 was 724.47K shares.
AXSM’s Market Performance
AXSM stock saw a decrease of -8.38% in the past week, with a monthly decline of -14.51% and a quarterly a decrease of -22.22%. The volatility ratio for the week is 4.90%, and the volatility levels for the last 30 days are 4.33% for Axsome Therapeutics Inc (AXSM).. The simple moving average for the past 20 days is -11.56% for AXSM’s stock, with a -12.22% simple moving average for the past 200 days.
Analysts’ Opinion of AXSM
Many brokerage firms have already submitted their reports for AXSM stocks, with Robert W. Baird repeating the rating for AXSM by listing it as a “Outperform.” The predicted price for AXSM in the upcoming period, according to Robert W. Baird is $108 based on the research report published on March 19, 2024 of the current year 2024.
UBS, on the other hand, stated in their research note that they expect to see AXSM reach a price target of $111. The rating they have provided for AXSM stocks is “Buy” according to the report published on February 06th, 2024.
RBC Capital Mkts gave a rating of “Outperform” to AXSM, setting the target price at $126 in the report published on January 25th of the current year.
AXSM Trading at -16.82% from the 50-Day Moving Average
After a stumble in the market that brought AXSM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -33.21% of loss for the given period.
Volatility was left at 4.33%, however, over the last 30 days, the volatility rate increased by 4.90%, as shares sank -16.65% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -30.68% lower at present.
During the last 5 trading sessions, AXSM fell by -8.38%, which changed the moving average for the period of 200-days by -6.44% in comparison to the 20-day moving average, which settled at $73.65. In addition, Axsome Therapeutics Inc saw -17.43% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at AXSM starting from Jacobson Mark L., who sale 24,662 shares at the price of $77.24 back on Apr 01 ’24. After this action, Jacobson Mark L. now owns 0 shares of Axsome Therapeutics Inc, valued at $1,904,942 using the latest closing price.
JEFFS ROGER, the Director of Axsome Therapeutics Inc, sale 2,347 shares at $71.61 during a trade that took place back on Mar 15 ’24, which means that JEFFS ROGER is holding 120,756 shares at $168,062 based on the most recent closing price.
Stock Fundamentals for AXSM
Current profitability levels for the company are sitting at:
- -0.86 for the present operating margin
- 0.9 for the gross margin
The net margin for Axsome Therapeutics Inc stands at -0.88. The total capital return value is set at -0.52. Equity return is now at value -159.21, with -52.02 for asset returns.
Based on Axsome Therapeutics Inc (AXSM), the company’s capital structure generated 0.48 points at debt to capital in total, while cash flow to debt ratio is standing at -0.81. The debt to equity ratio resting at 0.94. The interest coverage ratio of the stock is 35.93.
Currently, EBITDA for the company is -176.07 million with net debt to EBITDA at 0.82. When we switch over and look at the enterprise to sales, we see a ratio of 10.77. The receivables turnover for the company is 2.85for trailing twelve months and the total asset turnover is 0.46. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.63.
Conclusion
In conclusion, Axsome Therapeutics Inc (AXSM) has had a bad performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
